Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab
29. März 2023 13:41 ET
|
Psycheceutical Bioscience, Inc.
Psycheceutical Chief Visionary Officer Zappy Zapolin and CEO Chad Harman with MAPS Founder Rick Doblin MIAMI, March 29, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. ("Psycheceutical"...
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD
21. März 2023 12:50 ET
|
Psycheceutical Bioscience, Inc.
A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of applying NeuroDirect™ ketamine topical...
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
15. Februar 2023 11:30 ET
|
Psycheceutical Bioscience, Inc.
Psycheceutical enters into agreement with iNGENū to conduct human clinical trials of NeuroDirect™ ketamine topical in AustraliaPhase I trial will study 20 people to test the safety, tolerability,...
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD
02. Februar 2023 10:20 ET
|
Psycheceutical Bioscience, Inc.
MIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge brain delivery...
Psycheceutical Bioscience, Inc. Announces Medical Advisory Board
18. Oktober 2022 10:15 ET
|
Psycheceutical Bioscience, Inc.
MIAMI, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for...
Psycheceutical Bioscience, Inc.'s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council
04. Oktober 2022 10:14 ET
|
Psycheceutical Bioscience, Inc.
MIAMI, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (“Psycheceutical” or the “Company”) (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for...
Psycheceutical Bioscience, Inc.'s CEO to Present at the Life Sciences Investor Forum on September 15
13. September 2022 11:15 ET
|
Psycheceutical Bioscience, Inc.
MIAMI, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for...
Psycheceutical Bioscience, Inc. Enters into Exclusive Option to Acquire Vici Health Sciences
16. August 2022 10:14 ET
|
Psycheceutical Bioscience, Inc.
MIAMI, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (“Psycheceutical” or the “Company”) (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for...